

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Elisabeth M. Bock, et al.

Examiner: TO BE ASSIGNED

Serial No.: TO BE ASSIGNED

Art Unit: TO BE ASSIGNED

Filed: Herewith

Docket: 12754A

For: NEUROGENIC COMPOSITIONS
AND METHODS

Dated: February 12, 2001

Assistant Commissioner for Patents
United States Patent and Trademark Office
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

In connection with the filing of the above-identified application, kindly enter the following preliminary amendments.

IN THE SPECIFICATION:

Page 1, line 2, please insert the following text:

--CROSS REFERENCE TO RELATED APPLICATION

The present application is a divisional of Serial No. 09/393,433, filed September 10, 1999. --


CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"Express Mail" Mailing Label Number: EL739620738 US

Date of Deposit: February 12, 2001

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents and Trademarks, Washington, DC 20231.

Dated: February 12, 2001


Michelle Mustafa

IN THE CLAIMS:

Please cancel claims 1-3 and 9 without prejudice.

Please amend the claims as follows:

11. (Amended) The pharmaceutical composition of claim [9 or] 10, wherein said pharmaceutically acceptable carrier is liquid, semi-solid, or solid.

12. (Amended) The pharmaceutical composition of claim [9 or] 10, further comprising a neurotropic factor.

19. (Amended) The method of claims [15 or 16] 15-16 or 25, wherein said neurological condition is Parkinson's disease, Alzheimer's disease, Down's Syndrome, stroke, cardiac arrest, sciatic crush, spinal cord injury, injury to sensory neurons, or degenerative disease of the retina.

Please add the following claims:

24. A method of stimulating growth of neuronal cells, comprising administering an isolated multimeric Mts1 protein complex of claim 4 to said neuronal cells.

25. A method of treating a neurological condition in a subject, wherein said neurological condition is characterized by neuronal degeneration, death or injury, comprising administering to the subject a therapeutically effective amount of an isolated multimeric Mts1 protein complex of claim 4 and a pharmaceutically acceptable carrier.

REMARKS

Applicants request that the order of inventors be listed as follows: Elisabeth Marianne Bock, Vladimir Berezin and Eugene Lukanidin.

Applicants respectfully submit that the foregoing amendments do not introduce new subject matter. Support for added claims 24-25 can be found in the specification, e.g., at page 18, lines 11-18 and pages 35-39. It is respectfully submitted that the present case is in condition for allowance, which action is earnestly solicited.

Respectfully submitted,



Frank S. DiGiglio
Registration No. 31,346

SCULLY, SCOTT, MURPHY & PRESSER
400 Garden City Plaza
Garden City, New York 11530
(516) 742-4343
FSD/XZ:ab